I was asked about the clinical of thiazides and hyperglycemia. To be honest, studies aren’t that great surrounding this question, and the main ones I’m aware of and could find were very old. Here’s a quick breakdown of a couple of studies on the risk...
There may be a new option on the horizon for current insulin users! Insulin icodec is a new insulin option currently undergoing clinical trials. The most recent trial released for insulin icodec came out in November of 2020. The trial looked at the new insulin icodec,...
Obesity is a major risk factor for many comorbidities (hypertension, dyslipidemia, osteoarthritis, sleep apnea, heart disease, type 2 diabetes) and increases all-cause and cardiovascular mortality. With over 40% of Americans qualifying as obese (body mass index ≥30...
A new treatment for chronic weight management is likely on the way. In a recent trial, investigators looked at semaglutide for weight loss. The final results of the STEP1 trial (Semaglutide Treatment Effect in People with obesity) were recently reported in the New...
Technology continues to impact disease state management in remarkable ways. Monitoring of patients with diabetes is no exception. Both the American Diabetes Association and American Association of Clinical Endocrinologists/American College of Endocrinology make light...
The GLP-1 Agonists have grown significantly in their popularity and there are good reasons for that increase in use. They promote weight loss which is a big problem in the majority of our type 2 diabetes patients. In addition to this benefit, they have also been shown...
